Pergolide As Primary Therapy for Macroprolactinomas
dc.contributor.author | Orrego, John J. | en_US |
dc.contributor.author | Chandler, William F. | en_US |
dc.contributor.author | Barkan, Ariel L. | en_US |
dc.date.accessioned | 2006-09-11T19:02:43Z | |
dc.date.available | 2006-09-11T19:02:43Z | |
dc.date.issued | 2000-12 | en_US |
dc.identifier.citation | Orrego, John J.; Chandler, William F.; Barkan, Ariel L.; (2000). "Pergolide As Primary Therapy for Macroprolactinomas." Pituitary 3(4): 251-256. <http://hdl.handle.net/2027.42/47496> | en_US |
dc.identifier.issn | 1386-341X | en_US |
dc.identifier.issn | 1573-7403 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47496 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11788013&dopt=citation | en_US |
dc.description.abstract | The objective of this study is to determine whether pergolide therapy is an effective modality for the de novo treatment of patients with macroprolactinomas. Twenty-two consecutive patients with macroprolactinomas were included in the study and followed prospectively. These included 16 men and 6 women in whom pregnancy was not of concern. Pergolide was administered once or twice a day depending on the patient's preference. Ten patients received 0.1 mg daily as a maintenance regimen and in the others the daily dose ranged from 0.05 to 0.5 mg. Eight patients reported minor but tolerable side effects. One patient had to be switched to cabergoline because of intolerable nausea. After a mean of 12 months (range, 3–36), mean PRL levels declined from 3,135 ng/ml (range, 126–31,513) to 50 ng/ml (3–573), representing a mean PRL suppression of 88% (range, 0–99). PRL levels became normal in 15 patients and decreased to 25–40 ng/ml in 3 others. The mean tumor volume shrinkage was 25% or greater in 19 patients (86%), 50% or greater in 17 patients (77%), and 75% or greater in 10 patients (45%). Visual abnormalities were reversible after pergolide therapy in all but 1 of 12 patients with initially abnormal formal visual testing. Two out of 4 premenopausal women did not normalize PRL levels and had persistent oligomenorrhea. Testosterone was low in 14 men at presentation and normalized in 3 with pergolide therapy. We conclude that pergolide is a safe, inexpensive, and generally well-tolerated dopamine agonist for the treatment of macroprolactinomas in men and women in whom pregnancy is not of concern. In these specific populations, pergolide may become the first-line therapy for treatment of macroprolactinomas. | en_US |
dc.format.extent | 138587 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Diabetes | en_US |
dc.subject.other | Neurosurgery | en_US |
dc.subject.other | Macroprolactinoma | en_US |
dc.subject.other | Prolactin-secreting Pituitary Tumor | en_US |
dc.subject.other | Pergolide | en_US |
dc.subject.other | Dopamine Agonists | en_US |
dc.title | Pergolide As Primary Therapy for Macroprolactinomas | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Section of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, USA; Department of Veterans Affairs Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Section of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, USA; Department of Veterans Affairs Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Section of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, USA; Department of Veterans Affairs Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 11788013 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47496/1/11102_2004_Article_382165.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1012836331506 | en_US |
dc.identifier.source | Pituitary | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.